Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...

Antibody Actions

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

Hypersensitivity Reactions: Cytolytic Reactions

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...

Blood Typing

Blood Typing

Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cold agglutinin disease.

British journal of haematology·2026

Same author

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies.

Blood reviews·2026

Same author

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025

Same author

Treatment of autoimmune hemolytic anemia: novel and investigational approaches.

Minerva medica·2025

Same author

Expanding treatment options for warm autoimmune haemolytic anaemia.

The Lancet. Haematology·2025

Same author

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

EClinicalMedicine·2024

Search research articles

Related Experiment Video

Updated: Apr 27, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Complement, cold agglutinins, and therapy.

Sigbjørn Berentsen¹

¹HAUGESUND HOSPITAL.

|June 28, 2014

Summary

This summary is machine-generated.

A novel antibody, TNT003, targeting complement protein C1s effectively prevents cold agglutinin-induced in vitro hemolysis. This offers a potential new therapy for difficult-to-treat conditions.

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: Apr 27, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Depletion of Specific Cell Populations by Complement Depletion

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Immunology
Hematology
Complement System

Background:

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia.
Hemolysis in CAD is triggered by cold agglutinins (CA) activating the complement system.
Current treatments for CAD have limitations.

Purpose of the Study:

To investigate the efficacy of TNT003, a monoclonal antibody against C1s, in preventing CA-induced hemolysis.
To explore a novel therapeutic strategy for CAD.

Main Methods:

In vitro studies using cold agglutinins (CA).
Administration of TNT003, a mouse monoclonal antibody targeting complement protein C1s.
Assessment of hemolysis induction.

Main Results:

TNT003 prevented the induction of in vitro hemolysis by cold agglutinins (CA).
The antibody targets the early complement pathway initiated by C1s.

Conclusions:

Targeting C1s with TNT003 is a promising approach to inhibit CA-mediated hemolysis.
Further clinical studies are warranted to translate these findings into a viable therapeutic option for CAD.